Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study

MT Newswires Live

Jan 21

Syntara (ASX:SNT) said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.

The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.

Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.

The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605122162"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605122162\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605122162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 12:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605122162","market":"sg","top_or_hot":-1,"title":"Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study","media":"MT Newswires Live","content":"<html><body><p> Syntara (ASX:SNT) said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.</p><p>The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.</p><p>Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.</p><p>The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-21 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Syntara (ASX:SNT) said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.</p><p>The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.</p><p>Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.</p><p>The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605122162","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605122162","pubTimestamp":1768968426,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Syntara  said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK7096":"制药","SNT.AU":"Syntara Ltd","XAO.AU":"标普/澳交所 普通股指数","XKO.AU":"标普/澳交所 300指数"},"translate_title":"Syntara的胰腺癌候选药物将成为澳大利亚政府资助的临床研究的主题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1.5,"XAO.AU":1.5,"XJO.AU":1.5,"SNT.AU":1},"content_text":"Syntara (ASX:SNT) said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}